Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Lung Neoplasms 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Glioblastoma 1Carcinoma, Squamous Cell 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × bavituximab × Clear all
NCT03519997 2026-02-11

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Active not recruiting
35 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT05249569 2023-05-03

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
1 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡